Testing antibodies to predict heart muscle disease progression
Part of Genetic & congenital, Heart & circulation clinical trials.
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with dilated cardiomyopathy (a heart muscle condition).
- You do not have a serious infection that is not responding to treatment.
- You are not currently experiencing uncontrolled bleeding.
- You are not pregnant or breastfeeding.
- You are willing and able to follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a protein filtering treatment (immunoadsorption) for people with dilated cardiomyopathy who have a specific antibody linked to heart damage. It aims to see if removing these antibodies can improve heart function.
This study looks at how small blood vessels in the heart affect outcomes in people with dilated cardiomyopathy (an enlarged, weak heart). You may qualify if you have heart failure with a weak pump and no significant blockages in your main heart arteries.
This study is a registry for people with dilated cardiomyopathy (DCM)—a condition where the heart's main pumping chamber becomes enlarged and weak. It aims to learn more about DCM, especially in people from different ethnic backgrounds, by collecting health information over time.
This study aims to find and treat rare types of heart muscle disease early. If you have heart failure but no known heart disease, researchers will use MRI and other tests to see if a rare cause is behind your symptoms and then offer targeted treatment.
This study follows people with a specific genetic change (in the BAG3 gene) that causes heart muscle weakness, to learn more about how the condition progresses over time. It does not test a new drug, but it helps researchers understand the disease better, which may lead to future treatments.
This study offers genetic testing to adults with a type of heart muscle disease (non-ischemic cardiomyopathy or dilated cardiomyopathy) that is not caused by blocked arteries. The goal is to find genetic causes, which may guide treatment and family screening.
Hear when a new Dilated Cardiomyopathy (DCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.